About Thalys Medical Technology Group Corporation(603716)
Reply to inquiry letter on abnormal fluctuation of stock trading
Thalys Medical Technology Group Corporation(603716) ：
I have received the inquiry letter of Thalys Medical Technology Group Corporation(603716) on abnormal fluctuations in stock trading. After careful self-examination, I reply as follows:
Up to now, as the actual controller of Thalys Medical Technology Group Corporation(603716) (hereinafter referred to as ” Thalys Medical Technology Group Corporation(603716) “), as I control the enterprise saihai (Shanghai) Health Technology Co., Ltd. (hereinafter referred to as “saihai technology”, Thalys Medical Technology Group Corporation(603716) controlling shareholder), I plan to introduce strategic investors and improve the governance structure of listed companies through agreement transfer, There is great uncertainty whether relevant matters are implemented or not.
In addition, I have no major events that affect the abnormal fluctuation of Thalys Medical Technology Group Corporation(603716) stock price; There is no trading of the company’s shares during the abnormal fluctuation of this stock trading; There is no other major information that should be disclosed but not disclosed, including but not limited to major asset restructuring, issuance of shares, acquisition of listed companies, debt restructuring, business restructuring, asset stripping and asset injection.
Actual controller:
March 14, 2022
